ResearcherSpanish National Cancer Research CentreActive in the last 2 years
Jorge Dorado
Known by name at one institution; no external author ID yet. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2011: 1 paper · 2012: 2 papers · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper
Papers 6
- The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells. Co-author DOI 10.1136/gutjnl-2023-330995↗
- The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Co-author DOI 10.1136/gutjnl-2014-308470↗
- Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. Co-author DOI 10.1371/journal.pone.0076518↗
- Stem cells as the root of pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.yexcr.2011.11.007↗
- EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. First author DOI 10.1158/1078-0432.ccr-11-1270↗
- Pancreatic cancer stem cells: new insights and perspectives. Co-author DOI 10.1007/s00535-011-0422-x↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christopher Heeschen · 6 shared papers, 2011–2024 · strength 0.35
- Paper The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells. DOI 10.1136/gutjnl-2023-330995↗
- Paper Stem cells as the root of pancreatic ductal adenocarcinoma. DOI 10.1016/j.yexcr.2011.11.007↗
- Paper EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. DOI 10.1158/1078-0432.ccr-11-1270↗
- Bruno Sáinz · 2 shared papers, 2015–2024 · strength 0.18
- Paper The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells. DOI 10.1136/gutjnl-2023-330995↗
- Paper The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem … DOI 10.1136/gutjnl-2014-308470↗
- Ana García García de Paredes · 1 shared paper, 2024 · strength 0.14
- Adrián Palencia‐Campos · 1 shared paper, 2024 · strength 0.14
- Elisa Espinet · 1 shared paper, 2024 · strength 0.14
- Sonia Alcalá · 1 shared paper, 2024 · strength 0.14
- Susana Garcı́a-Silva · 1 shared paper, 2024 · strength 0.14
- Matthias M. Gaida · 1 shared paper, 2024 · strength 0.14
- Juan Carlos López-Gil · 1 shared paper, 2024 · strength 0.14
- Carmen E. Guerra · 1 shared paper, 2024 · strength 0.14
- Alfredo Carrato · 1 shared paper, 2024 · strength 0.14
- Victor Javier Sanchez-Arevalo Lobo · 1 shared paper, 2024 · strength 0.14
- Carolina de la Pinta · 1 shared paper, 2024 · strength 0.14
- Julie Earl · 1 shared paper, 2024 · strength 0.14
- Michele Cioffi · 3 shared papers, 2012–2015 · strength 0.12
- Paper EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. DOI 10.1158/1078-0432.ccr-11-1270↗
- Paper The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem … DOI 10.1136/gutjnl-2014-308470↗
- Paper Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. DOI 10.1371/journal.pone.0076518↗
- Enza Lonardo · 3 shared papers, 2011–2015 · strength 0.12
- Paper The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem … DOI 10.1136/gutjnl-2014-308470↗
- Paper Pancreatic cancer stem cells: new insights and perspectives. DOI 10.1007/s00535-011-0422-x↗
- Paper Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. DOI 10.1371/journal.pone.0076518↗
- Anamaria Balic · 2 shared papers, 2012–2013 · strength 0.08
- Sara Maria David Trabulo · 2 shared papers, 2013–2015 · strength 0.08
- Manuel M. Hidalgo · 2 shared papers, 2013–2015 · strength 0.08
- Stephan A. Hahn · 1 shared paper, 2015 · strength 0.04
- Patricia Sancho · 1 shared paper, 2013 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.